Yamauti Sueli Miyuki, Bonfim José Ruben de Alcântara, Barberato-Filho Silvio, Lopes Luciane Cruz
Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade de Sorocaba. Rodovia Raposo Tavares Km 92,5. 18023-000 Sorocaba SP Brasil.
Instituto de Saúde, Secretaria de Estado da Saúde de São Paulo. São Paulo SP Brasil.
Cien Saude Colet. 2017 Mar;22(3):975-986. doi: 10.1590/1413-81232017223.07742016.
One strategy to implement the rational use of medicines is the adoption of an 'essential medicines list'. The objective of this study was to analyze the list of medicines contained in the Brazilian National Relation of Essential Medicines (Rename, 2013) in terms of essentiality and rationality. Essentiality was determined by comparing this list to the 18th Essential Medicines List (EML) published by the World Health Organization (WHO). Drugs which were part of the Brazilian National Relation of Essential Medicines but not included in the EML were assessed using the classification described in La revue Prescrire to detect medications without added therapeutic value. It was discovered that the Brazilian National Relation of Essential Medicines contains 190 medications not included in the EML, of which 63 have no added therapeutic value. In addition, discrepancies were identified between the recommendations of the WHO and the drugs included in the Brazilian National Relation of Essential Medicines. It is concluded that drugs that are non-essential and provide no added therapeutic value should not be included in a list of essential medicines funded by the three Brazilian federal entities.
实施合理用药的一项策略是采用“基本药物清单”。本研究的目的是从必要性和合理性方面分析巴西国家基本药物目录（Rename，2013年）中包含的药物清单。通过将该清单与世界卫生组织（WHO）发布的第18版基本药物清单（EML）进行比较来确定必要性。对于属于巴西国家基本药物目录但未列入EML的药物，使用《Prescrire评论》中描述的分类方法进行评估，以检测没有附加治疗价值的药物。研究发现，巴西国家基本药物目录包含190种未列入EML的药物，其中63种没有附加治疗价值。此外，还发现了WHO的建议与巴西国家基本药物目录中包含的药物之间存在差异。得出的结论是，非必需且没有附加治疗价值的药物不应列入由巴西三个联邦实体资助的基本药物清单。
